Prostaglandin E1 restores endothelial progenitor cell function in systemic sclerosis.

Area of Science:

• Vascular Biology
• Immunology
• Regenerative Medicine

Background:

• Systemic sclerosis (SSc) involves microvascular injury and impaired angiogenesis, with dysfunctional endothelial progenitor cells (EPCs).
• EPC subsets like CFU-ECs and ECFCs are crucial for vascular repair but are reduced in SSc patients.
• The therapeutic potential of Prostaglandin E1 (PGE1) on EPCs in SSc remains unexplored.

Purpose of the Study:

• To investigate PGE1's effect on EPC numbers (CFU-ECs and ECFCs) in SSc patients with Raynaud's phenomenon (RP).
• To evaluate PGE1's potential role in promoting vascular repair in SSc.

Main Methods:

• Evaluated PGE1's impact on EPC levels in 12 SSc patients with RP and 5 healthy controls (HCs).
• Quantified CFU-EC and ECFC clusters pre- and post-intravenous PGE1 treatment (8-9 days).
• Utilized standardized culture methods and statistical analyses to compare EPC counts between groups and time points.

Main Results:

• SSc patients exhibited significantly lower baseline CFU-EC and ECFC counts compared to HCs.
• PGE1 treatment significantly increased CFU-EC and ECFC clusters in SSc patients, normalizing levels to those of HCs.
• A significant difference in EPC cluster count changes was observed between SSc patients and HCs post-treatment.

Conclusions:

• PGE1 treatment effectively restores CFU-EC and ECFC levels in SSc patients.
• These findings indicate PGE1's therapeutic potential in repairing vascular damage associated with SSc microvasculopathy.
• PGE1 offers benefits beyond vasodilation, supporting its consideration for SSc treatment.